Table 2.
Comparison of clinical, pathological, and treatment characteristics between patients with NP and TR
| Characteristic | Method 1 | Method 2 | ||||
|---|---|---|---|---|---|---|
|
| ||||||
| TR N=201 (%) |
NP N=196 (%) |
P | TR N=185 (%) |
NP N=212(%) |
P | |
| Age (mean) | ||||||
| At primary | 47.4 | 47.6 | .79 | 47.5 | 47.5 | .95 |
| At IBTR | 52.9 | 55.9 | .03 | 53.1 | 55.1 | .08 |
| Time to IBTR in years | 5.4 | 7.6 | <.0001* | 5.5 | 7.4 | .0001* |
| Follow-up time in years |
10.8 | 13.4 | .0006 | 11.0 | 13.1 | .007 |
| Contralateral breast cancer | .04 | .02 | ||||
| yes | 19 (9.4) | 32 (16.3) | 16 (8.7) | 35 (16.5) | ||
| No | 182 (90.6) | 164 (86.7) | 169 (91.3) | 177 (83.5) | ||
| XRT for primary tumor |
.81 | .36 | ||||
| Yes | 170 (84.6) | 164 (83.7) | 159 (86.0) | 175 (82.6) | ||
| No | 31 (15.4) | 32 (16.3) | 26 (14.0) | 37 (17.4) | ||
| Adjuvant chemotherapy for primary tumor |
.41 | .39 | ||||
| Yes | 57 (28.4) | 63 (32.1) | 52 (28.1) | 68 (32.1) | ||
| No | 144 (71.6) | 133 (67.9) | 133 (71.9) | 144 (67.9) | ||
| Adjuvant hormonal therapy for primary tumor | .18 | .33 | ||||
| Yes | 39 (19.4) | 49 (25.0) | 37 (20.0) | 51 (24.1) | ||
| No | 162 (80.6) | 147 (75.0) | 148 (80.0) | 161 (75.9) | ||
| ER status of primary | .19^ | .81^ | ||||
| Positive | 86 (56.6) | 99 (63.9) | 83 (61.0) | 102 (59.7) | ||
| Negative | 66 (43.4) | 56 (36.1) | 53 (39.0) | 69 (40.3) | ||
| PR status of primary | .29^ | .96^ | ||||
| Positive | 71 (51.4) | 86 (57.7) | 68 (54.8) | 89 (54.6) | ||
| Negative | 67 (48.6) | 63 (42.3) | 56 (45.2) | 74 (45.4) | ||
| HER-2 status of primary |
.88^ | .97^ | ||||
| Positive | 17 (25.4) | 17 (24.3) | 14 (25.0) | 20 (24.7) | ||
| Negative | 50 (74.6) | 53 (75.7) | 42 (75.0) | 61 (75.3) | ||
| Chemotherapy for IBTR | .009 | .04 | ||||
| Yes | 103 (51.2) | 75 (38.3) | 93 (20.3) | 85 (40.1) | ||
| No | 98 (48.8) | 121 (61.7) | 92 (49.7) | 127 (59.9) | ||
| Hormonal therapy for IBTR | .58 | .65 | ||||
| Yes | 72 (35.8) | 65 (33.2) | 66 (35.7) | 71 (33.5) | ||
| No | 129 (64.2) | 131 (66.8) | 119 (64.3) | 141 (66.5) | ||
| ER status of IBTR | .93^ | .65^ | ||||
| Positive | 102 (64.2) | 106 (64.6) | 94 (65.7) | 114 (63.3) | ||
| Negative | 57 (35.8) | 58 (35.4) | 49 (32.3) | 66 (36.7) | ||
| PR status of IBTR | .31^ | .26^ | ||||
| Positive | 81 (56.3) | 73 (50.3) | 74 (56.9) | 80 (50.3) | ||
| Negative | 63 (43.7) | 72 (50.0) | 56 (43.1) | 79 (49.7) | ||
| HER-2 status of IBTR | .48^ | .13^ | ||||
| Positive | 17 (19.1) | 24 (23.3) | 12 (15.8) | 29 (25.0) | ||
| Negative | 72 (80.9) | 79 (76.7) | 64 (84.2) | 87 (75.0) | ||
| Surgery for IBTR | .006 | .01 | ||||
| No surgery | 21 (10.5) | 6 (3.1) | 20 (10.8) | 7 (3.3) | ||
| SM | 30 (14.9) | 23 (11.7) | 24 (13.0) | 29 (13.7) | ||
| TM | 150 (74.6) | 167 (85.2) | 141 (76.2) | 176 (83.0) | ||
| Systemic recurrence | <.0001 | <.0001 | ||||
| Yes | 85 (42.3) | 21 (10.7) | 78 (42.2) | 28 (13.2) | ||
| No | 116 (57.7) | 175 (89.3) | 107 (57.8) | 184 (86.8) | ||
IBTR indicates ipsilateral breast tumor recurrence; ER indicates estrogen receptor; PR indicates progesterone receptor; HER-2, human epidermal growth factor receptor 2; SM indicates segmental mastectomy; TM indicates total mastectomy;
*
Ranksum test,
^
excluded the unknown category